RYTHMODAN CAPSULE

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

DISOPYRAMIDE

Mevcut itibaren:

CHEPLAPHARM ARZNEIMITTEL GMBH

ATC kodu:

C01BA03

INN (International Adı):

DISOPYRAMIDE

Doz:

100MG

Farmasötik formu:

CAPSULE

Kompozisyon:

DISOPYRAMIDE 100MG

Uygulama yolu:

ORAL

Paketteki üniteler:

84

Reçete türü:

Prescription

Terapötik alanı:

CLASS IA ANTIARRYTHMICS

Ürün özeti:

Active ingredient group (AIG) number: 0111559001; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2006-05-04

Ürün özellikleri

_Pr _
_RYTHMODAN_
_®_
_ _
_Page 1 of 22 _
PRODUCT MONOGRAPH
Pr
RYTHMODAN
®
Disopyramide capsules BP
100 mg
Antiarrhythmic Agent
ATC code: C01BA03
Date of Revision:
December 16, 2020
Submission Control No.:
246461
Tel: 1-888-XEDITON
L5N 1W1
Mississauga,
Ontario
2000
Argentia Rd.
Xediton Pharmaceuticals Inc.
Importer/Distributor:
Germany
17489 Greifswald
Ziegelhof 24
CHEPLAPHARM Arzneimittel GmbH
_Pr _
_RYTHMODAN_
_®_
_ _
_Page 2 of 22 _
TABLE OF CONTENTS
1 THERAPEUTIC CLASSIFICATION
.........................................................................................
3
2 ACTION AND CLINICAL PHARMACOLOGY
......................................................................
3
3 INDICATIONS AND CLINICAL USE
......................................................................................
4
4 CONTRAINDICATIONS
...........................................................................................................
4
5 WARNINGS
................................................................................................................................
5
6 PRECAUTIONS
..........................................................................................................................
8
7 ADVERSE REACTIONS
..........................................................................................................
12
8 SYMPTOMS AND TREATMENT OF OVERDOSAGE
........................................................ 14
9 DOSAGE AND ADMINISTRATION
......................................................................................
15
10 PHARMACEUTICAL INFORMATION
................................................................................
16
11 AVAILABILITY OF DOSAGE FORMS
...............................................................................
16
12 PHARMACOLOGY
................................................................................................................
17
13 TOXICOLOGY
.........................................................................................................